Enterovirus diversity may limit treatment advances
Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
By
Andrea Surnit
September 8, 2026
Clinical Scorecard: Enterovirus diversity may limit treatment advances
At a Glance
Category Detail
Condition Enterovirus infections in children Key Mechanisms Viral entry mechanisms, rapid evolution, antigenic variation Target Population Pediatric patients, particularly those with severe disease Care Setting Pediatric clinical settings
Key Highlights
Molecular testing is central to EV diagnosis with over 95% sensitivity. Treatment remains primarily supportive; no antiviral drug is approved for routine use. Investigational antiviral candidates have stalled in development. The inactivated EV-A71 vaccine shows over 90% efficacy against severe HFMD. Challenges include genetic diversity and lack of cross-protection among EVs. Guideline-Based Recommendations
Diagnosis
Use molecular testing alongside clinical manifestations and epidemiologic information. Management
Supportive care including fluid management, antipyresis, and seizure control. Monitoring & Follow-up
Monitor for severe disease and complications, particularly in immunocompromised patients. Risks
Severe disease and death can occur, especially in vulnerable populations. Patient & Prescribing Data
Pediatric patients with enterovirus infections
Supportive care is the mainstay; investigational treatments are largely unproven.
Clinical Best Practices
Prioritize broad-spectrum antiviral agents with high resistance barriers. Consider pediatric safety in treatment approaches. Related Resources & Content
